New Delhi: Ahead of the World Health Day, Atal Innovation Mission, NITI Aayog, AGNIi, Foundation for Innovation and Technology Transfer (FITT), IIT-Delhi, Pfizer and Social Alpha have come together to launch the Pfizer INDovation Program to support breakthrough healthcare innovations by start-ups in India.
Social Alpha is the core implementation partner responsible for executing the program.
This is Version 2.0 of the Pfizer IIT-Delhi Innovation and IP Program and is one of Pfizer’s CSR initiatives. In Version 1, Pfizer successfully incubated 9 healthcare innovators and supported 19 IP filings. Now, in the first year of Version 2.0, three winning start-ups each in the areas of Oncology and Digital Health, will receive a grant of up to INR 65 lakh each for product trials, pilot studies, and product market launches to accelerate the lab-to-market journey of their innovation. This is one of the largest such programs, both by grant value and partnerships, to focus on incubating and commercializing healthcare start-ups in the country.
AIM and NITI Aayog will provide the startups with access to their entire network of incubators and facilities via co-incubation and will also provide technical and strategic advisory to support to both the program and the startups. The Indian Institute of Technology, Delhi (IIT Delhi), will be the principal incubation partner while customized incubation support will be provided across technology incubation centers such as the IITs, other major technology institutes and incubation network of Atal Innovation Mission across India. Social Alpha, as the implementation partner, will support start-ups to accelerate their lab-to-market journey.
The program is also being supported by AGNIi, PATH, AHPI, St Johns Research Institute, HCG Hospitals, Cytecare Hospitals, FICCI, UNHIEX, Google for Startups, Design Alpha, HIMSS, Marico Innovation Foundation, and TenX2.
A nationwide call for applications in a grand challenge format will be announced to invite Digital Health and Oncology start-ups working on the identified priority problem statements. Eligible participants include:
Medical devices and diagnostics start-ups and companies with product stage of Technological Readiness Level (TRL) 4 or above
Start-ups or companies in artificial intelligence, big data analysis, IoTs, software development and bioinformatics at TRL level 5 or above.